16 results
8-K
EX-99.1
CGTX
Cognition Therapeutics Inc
24 Aug 23
Regulation FD Disclosure
7:00am
. Cognition Therapeutics – Our Company
6 Within the amyloid hypothesis, oligomers are a pathogenic form produced early in disease Innovation lies
424B4
CGTX
Cognition Therapeutics Inc
14 Nov 22
Prospectus supplement with pricing info
6:02am
impact the timing of the commercial launch of the product.
The Food and Drug Administration Safety and Innovation Act established a category of drugs
DRS
CGTX
Cognition Therapeutics Inc
20 Oct 22
Draft registration statement
12:00am
of the commercial launch of the product.
The Food and Drug Administration Safety and Innovation Act established a category of drugs referred to as “breakthrough
10-K
6gxrx etxy9dgtks
30 Mar 22
Annual report
7:40am
10-Q
02lixvs 612bao
17 Nov 21
Quarterly report
5:15pm
424B4
yjbu8i5juyi
12 Oct 21
Prospectus supplement with pricing info
4:11pm
S-1
EX-10.2
j4b5e4xrte
19 Jul 21
IPO registration
7:02am
S-1
lel21itilx6w7q
19 Jul 21
IPO registration
7:02am
DRS/A
jqq phwqn25wlv57g8ss
23 Jun 21
Draft registration statement (amended)
12:00am
DRS
k61x2g fc
7 May 21
Draft registration statement
12:00am
DRS
EX-10.2
ugpeimheabk970wi7p52
7 May 21
Draft registration statement
12:00am
- Prev
- 1
- Next